APOC3 and ANGPTL3 inhibitors provide potent triglyceride reduction in monogenic and refractory forms, while metabolic agents such as GLP-1 receptor agonists target the hepatic and insulin-resistant components characteristic of polygenic or MASLD-associated hypertriglyceridemia. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.